title: A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.
abstract: BACKGROUND
  Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness. The present study was designed to test whether rizatriptan is also effective in protecting against visually-induced motion sickness and to test whether rizatriptan blocks the augmentation of motion sickness by head pain.
  
  
  METHODS
  Using randomized double-blind, placebo-controlled methodology, 10 females, 6 with migrainous vertigo (V+) and four without vertigo (V-) received 10 mg rizatriptan or placebo two hours prior to being stimulated by optokinetic stripes. Visual stimulation was coupled with three pain conditions: no pain (N), thermally-induced hand pain (H) and temple pain (T). Motion sickness and subjective discomfort were measured.
  
  
  RESULTS
  Motion sickness was less after pre-treatment with rizatriptan for 4 of 10 subjects and more for 5 of 10 subjects. Augmentation of motion sickness by head pain was seen in 6 of 10 subjects; this effect was blunted by rizatriptan in 4 of these 6 subjects. Subjective discomfort was significantly more noticeable in V+ subjects as compared with V- subjects.
  
  
  CONCLUSIONS
  These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
authors.affiliation: Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA. furman@pitt.edu
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Furman
authors.forename: Dawn A
authors.initials: DA
authors.lastname: Marcus
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy*; D009041:Motion Sickness / Q000150:complications* / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan
references.citation: Eur J Pharmacol. 1997 Jun 5;328(1):37-40
references.pmid: 9203565
references.citation: Exp Brain Res. 2008 Sep;190(2):165-77
references.pmid: 18566806
references.citation: Audiol Neurootol. 2008;13(2):113-22
references.pmid: 18057875
references.citation: Brain Res Bull. 1998 Nov 15;47(5):395-406
references.pmid: 10052567
references.citation: Eur J Pharmacol. 1994 Feb 21;253(1-2):53-60
references.pmid: 8013549
references.citation: Headache. 2001 Jun;41(6):604-5
references.pmid: 11437901
references.citation: Cephalalgia. 2008 Sep;28(9):988-90
references.pmid: 18624802
references.citation: Expert Opin Pharmacother. 2005 Dec;6(15):2691-7
references.pmid: 16316307
references.citation: Aerosp Med. 1968 May;39(5):453-5
references.pmid: 5648730
references.citation: Br J Pharmacol. 1995 Mar;114(5):931-4
references.pmid: 7780647
references.citation: Headache. 2007 Nov-Dec;47(10):1427-35
references.pmid: 18052952
references.citation: Headache. 2001 Sep;41(8):754-63
references.pmid: 11576198
references.citation: Brain. 1984 Dec;107 ( Pt 4):1123-42
references.pmid: 6334543
references.citation: Drugs. 2005;65(18):2557-67
references.pmid: 16392873
references.citation: Cephalalgia. 2002 Mar;22(2):117-24
references.pmid: 11972579
references.citation: Cephalalgia. 2002 May;22(4):271-81
references.pmid: 12100089
references.citation: Headache. 1981 Sep;21(5):227-31
references.pmid: 7287423
references.citation: Neurology. 2006 Sep 26;67(6):1028-33
references.pmid: 17000973
references.citation: Brain. 2004 Mar;127(Pt 3):526-34
references.pmid: 14749288
references.citation: J Headache Pain. 2008 Jun;9(3):185-8
references.pmid: 18427727
references.citation: Neuroscience. 1993 Feb;52(4):941-9
references.pmid: 8450981
references.citation: Med Sci Monit. 2004 May;10(5):CR197-201
references.pmid: 15114269
references.citation: Brain Res Brain Res Rev. 1995 Jan;20(1):24-46
references.pmid: 7711766
references.citation: Neurology. 2001 Feb 27;56(4):436-41
references.pmid: 11222783
references.citation: Nat Med. 1995 Jul;1(7):658-60
references.pmid: 7585147
references.citation: Exp Brain Res. 2007 Apr;178(4):477-87
references.pmid: 17256169
references.citation: Med Sci Monit. 2006 Jan;12(1):PI1-7
references.pmid: 16369474
references.citation: Cochrane Database Syst Rev. 2004;(3):CD002851
references.pmid: 15266468
references.citation: Headache. 2004 Apr;44(4):328-32
references.pmid: 15109357
references.citation: Physiol Behav. 2002 Dec;77(4-5):469-75
references.pmid: 12526985
references.citation: Expert Rev Neurother. 2005 Sep;5(5):597-603
references.pmid: 16162083
references.citation: Drugs. 2002;62(10):1539-74
references.pmid: 12093318
references.citation: Cephalalgia. 2004;24 Suppl 1:9-160
references.pmid: 14979299
references.citation: Expert Opin Pharmacother. 2003 Oct;4(10):1709-15
references.pmid: 14521481
references.citation: J Vestib Res. 2005;15(5-6):327-32
references.pmid: 16614477
references.citation: Headache. 2005 Jun;45(6):653-6
references.pmid: 15953297
references.citation: Aviat Space Environ Med. 1999 Nov;70(11):1077-80
references.pmid: 10608604
references.citation: Cephalalgia. 2008 Jan;28(1):72-7
references.pmid: 17999681
references.citation: Pharmacol Biochem Behav. 2002 Nov;73(4):979-89
references.pmid: 12213545